XTL Biopharmaceuticals Postpones Shareholders' Meeting Due to Quorum Issue

XTL Biopharmaceuticals has postponed its annual and extraordinary shareholders' meeting due to a quorum issue. The meeting has been rescheduled to July 28, 2025. This delay may impact the company's operations and stakeholder relations. According to Spark, TipRanks' AI Analyst, XTLB is a "Underperform" stock due to persistent losses, weak cash flow, and unattractive valuation metrics.

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB) has announced the postponement of its annual and extraordinary shareholders' meeting, originally scheduled for July 2, 2025, due to a lack of quorum. The company has rescheduled the meeting for July 28, 2025, at 4:00 p.m. Israel Standard Time [1][2].

The decision to postpone the meeting was communicated via a press release and a filing with the U.S. Securities and Exchange Commission. XTL Biopharmaceuticals, based in Ramat Gan, Israel, stated that the postponement adheres to the procedures outlined in the meeting's convening notice.

The company is an intellectual property portfolio, holding 100% of The Social Proxy Ltd., a web data company. Additionally, it has sublicensed an IP portfolio related to hCDR1 for the treatment of lupus disease (SLE). No further details regarding the agenda of the postponed meeting or the issues requiring shareholder approval were provided in the filing.

The postponement of the meeting may have implications for the company's operations and stakeholder relations. According to Spark, TipRanks' AI Analyst, XTLB is currently rated as an "Underperform" stock due to persistent losses, weak cash flow, and unattractive valuation metrics.

References:
[1] https://www.investing.com/news/sec-filings/xtl-biopharmaceuticals-postpones-shareholder-meeting-due-to-lack-of-quorum-93CH-4144448
[2] https://ng.investing.com/news/sec-filings/xtl-biopharmaceuticals-postpones-shareholder-meeting-due-to-lack-of-quorum-93CH-2017150